KRAS and neoplasm: In addition to BM-derived SNVs, we detected an additional 483 SNVs in the plasma across these 22 patients that were not present in the BM, including KRAS, NRAS, TP53, and BRAF mutations, suggesting ctDNA may capture spatial tumor heterogeneity not present in BM biopsies.